🩺What is Osteoarthritis?
The HAQ was developed by Dr. James Fries and colleagues at Stanford University in 1980 and has become the most widely used functional status measure in rheumatology. The HAQ-DI assesses 20 questions across 8 domains: dressing/grooming (2 items), arising (2 items), eating (3 items), walking (2 items), hygiene (3 items), reach (2 items), grip (3 items), and activities (3 items). Each domain is scored 0 (without any difficulty) to 3 (unable to do). The total HAQ-DI score is the average of the 8 domain scores, ranging from 0 (no disability) to 3 (severe disability).
📊Clinical Assessment & Risk Scoring
Healthcare professionals use these validated clinical calculators, diagnostic scales, and risk scoring systems to assess the severity, prognosis, or therapeutic dosing requirements for Osteoarthritis:
HAQ-DI — Health Assessment Questionnaire Disability Index
The Health Assessment Questionnaire Disability Index (HAQ-DI) is a validated patient-reported outcome measure that assesses functional disability across eight domains of daily living: dressing, arising, eating, walking, hygiene, reach, grip, and activities. It is widely used in rheumatoid arthritis and other rheumatic diseases.
🧬Diagnostic Logic & Scoring Breakdown
The HAQ-DI score is calculated by averaging the scores from 8 functional domains. Each domain is scored 0-3: 0 = without any difficulty, 1 = with some difficulty, 2 = with much difficulty, 3 = unable to do. Domain scores are adjusted upward if the patient requires aids, devices, or assistance from another person for that domain (minimum score 2 if aids/devices used). The final score ranges from 0 (no disability) to 3 (severe disability).
📢Clinical Significance & Implications
The HAQ-DI is the most widely used functional status measure in rheumatology and is predictive of long-term outcomes including work disability, joint replacement surgery, and mortality in RA. A HAQ-DI score >1 is associated with significant functional limitation and increased healthcare utilization. The minimal clinically important difference (MCID) for HAQ-DI is 0.22-0.25. The HAQ-DI is the primary functional endpoint in most RA clinical trials and is recommended by OMERACT and ACR for core outcome measurement.
💡 Clinical Assessment Scenario Example
A 55-year-old woman with RA: Dressing=1, Arising=2, Eating=0, Walking=1, Hygiene=2, Reach=1, Grip=2, Activities=2. HAQ-DI = (1+2+0+1+2+1+2+2)/8 = 11/8 = 1.38. Moderate disability. Recommendation: Escalate DMARD, refer to occupational therapy.
💊Common Medications & Interventions
The following pharmacological therapies and substances are commonly referenced or adjusted based on the clinical assessment of Osteoarthritis:
⚠️Clinical Assessment Pitfalls
❌ Mistake: Not adjusting domain scores upward when the patient uses aids or devices
✅ Correction: According to the standard HAQ scoring, if a patient uses aids, devices, or requires assistance from another person for a domain, the minimum score for that domain should be 2 (with much difficulty), even if the patient reports less difficulty. This adjustment ensures accurate representation of true functional status.
❌ Mistake: Using HAQ-DI alone without assessing disease activity (DAS28)
✅ Correction: HAQ-DI measures functional disability, which is influenced by both disease activity and structural damage. It should be interpreted alongside disease activity measures like DAS28 to differentiate active inflammation from permanent joint damage as a cause of disability.
🚑When to Seek Medical Attention
This reference supports clinical assessment of Osteoarthritis; it does not replace urgent evaluation. Seek prompt in-person medical care if symptoms are severe, rapidly worsening, or life-threatening, or if you are unsure about a diagnosis or treatment plan. Patients should always consult their physician before starting or changing any therapy.
❓Frequently Asked Questions
Q: What is the minimal clinically important difference (MCID) for HAQ-DI?
The MCID for HAQ-DI is approximately 0.22-0.25 points on the 0-3 scale. In clinical trials, a change of 0.22-0.25 is considered a small but meaningful improvement. A change of 0.5 is considered moderate improvement, and a change of 1.0 or more is considered major improvement. The HAQ-DI is sensitive to change with effective DMARD therapy.
Q: Can HAQ-DI distinguish between disability from active inflammation vs permanent joint damage?
The HAQ-DI measures overall functional status but does not distinguish between reversible disability from active inflammation and irreversible disability from structural joint damage. To make this distinction, HAQ-DI should be interpreted alongside disease activity measures (DAS28, CRP/ESR) and imaging findings. Improvement in HAQ-DI with treatment suggests reversible inflammatory component, while persistent HAQ-DI elevation despite controlled inflammation suggests structural damage.